Published

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in psychiatry
Date: 2022-12-31
Source: PubMed
DOI: 10.3389/fpsyt.2023.1191970
PubMed: 37252138

Authors

Blest-Hopley G Amit BH O'Neill A Ruffell SGD

Watch author

Topics and keywords

psilocybin Safety Other cannabinoids cannabis hallucinogenic psilocybin psychedelics

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidencePsychedelics. · 2025-10-27 Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexiaPsychedelics. · 2026-02-02 Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reportsPsychedelics · 2025-11-19 Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondentsPsychedelics · 2025-11-14 Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not helpPsychedelics. · 2024-11-06 Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorderPsychedelics. · 2024-09-23 An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United StatesPsychedelics. · 2024-09-12 Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depressionPsychedelics. · 2024-08-11